Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani, Issues Letter to Shareholders
December 15, 2022 09:00 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY) (“Clearmind” or the “Company”), a biotech company developing...
Israeli Based Biotech Company Clearmind Completes IND-Enabling Studies for CMND-100
December 13, 2022 09:00 ET
|
Clearmind Medicine Inc.
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel / Vancouver, Canada, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq,CSE:...
Israeli Biotech Clearmind Medicine Appoints ex-Red Bull Executive Special Advisor for Developing MEAI as Alcohol Substitute
December 09, 2022 09:02 ET
|
Clearmind Medicine Inc.
Nicholas Kadysh, a former Red Bull Canada and Juul Labs Canada executive, is an expert on regulatory issues VANCOUVER, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND),...
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
November 23, 2022 08:45 ET
|
Clearmind Medicine Inc.
VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development...
Clearmind Medicine Announces Closing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
November 17, 2022 11:43 ET
|
Clearmind Medicine Inc.
VANCOUVER, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of...
Clearmind Medicine Announces Pricing of US$7.5 Million Public Offering and Uplisting to the Nasdaq Capital Market
November 14, 2022 19:09 ET
|
Clearmind Medicine Inc.
VANCOUVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq and CSE: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of...
Clearmind Medicine Featured in "Psychedelics Tonight," Streaming on ALTRD.TV
October 11, 2022 09:00 ET
|
Clearmind Medicine Inc.
The first episode, "Psychedelic Novelty - Before it was Cool," introduces the company's proprietary molecule MEAI VANCOUVER, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND),...
Clearmind Announces Notice of Proposed Stock Consolidation
September 25, 2022 09:36 ET
|
Clearmind Medicine Inc.
VANCOUVER, Sept. 25, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and...
Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
September 22, 2022 08:30 ET
|
Clearmind Medicine Inc.
Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd. VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine...
Clearmind Medicine Announces Share-Based Payment for one of the Company's Consultants
September 16, 2022 16:30 ET
|
Clearmind Medicine Inc.
VANCOUVER, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "Company"), a biotech company focused on discovery and...